General Information of Drug (ID: DMB6FN7)

Drug Name
GNF-PF-85 Drug Info
Synonyms
GNF-PF-85; 3-[(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]naphthalen-2-ol; 3-({5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}amino)naphthalen-2-ol; BAS 01083131; AC1LFFF4; Oprea1_463466; Oprea1_430691; SCHEMBL4939616; CHEMBL487518; BDBM24409; ZINC267589; AKOS024371314; Triazolopyrimidine-Based Compound, 16; MCULE-8335313178; ST51007753; SR-01000326143; SR-01000326143-1; 3-(5-Methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-naphthalen-2-ol
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
777193
TTD Drug ID
DMB6FN7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [2]
Leflunomide DMR8ONJ Arthritis FA20 Approved [3]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [4]
Atovaquone DMY4UMW Fungal infection 1F29-1F2F Approved [5]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [6]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [7]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [7]
Orotate DMMB29S Discovery agent N.A. Investigative [8]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [7]
1,4-Naphthoquinone DMTCMH7 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [1]

References

1 Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falcipa... J Med Chem. 2008 Jun 26;51(12):3649-53.
2 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
3 Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
4 Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
5 Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
6 Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.